This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D’Amico, A. V. Articles by Schultz, D. Search for Related Content PubMed PubMed Citation Articles by D’Amico, A. V. Articles by Schultz, D. Social Bookmarking                            What's this?

Determinants of Prostate Cancer–Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer

From the Departments of Radiation Oncology and Pathology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA, and Department of Mathematics, Millersville University, Millersville, PA.

Address reprint requests to Anthony V. D’Amico, MD, PhD, Department of Radiation Oncology, Brigham and Women’s Hospital, 75 Francis St, L-2 Level, Boston, MA 02215; email: adamico{at}lroc.harvard.edu

PURPOSE: Identifying pretreatment and posttreatment predictors of time to prostate cancer–specific death (PCSD) after external-beam radiation therapy (RT) was the subject of this study.

PATIENTS AND METHODS: A Cox regression analysis was used to evaluate the ability of the pretreatment risk group to predict time to PCSD for 381 patients who underwent RT for clinically localized prostate cancer. Posttreatment factors analyzed for the 94 patients who experienced prostate-specific antigen (PSA) failure included the time to PSA failure, the posttreatment PSA doubling time (DT), and the timing of salvage hormonal therapy.

RESULTS: Despite the median age of 73 years at diagnosis, 45% of patients with high-risk disease were estimated to die from prostate cancer within 10 years after RT compared with 0% (P = .004) and 6% (P = .05) for patients with low- or intermediate-risk disease, respectively. Predictors of time to PCSD after PSA failure included PSA DT (P = .01) and delayed use of hormonal therapy (P .002). Nearly identical estimates of PCSD and all-cause death after PSA failure were noted for patients with a short PSA DT (ie, 12 months).

CONCLUSION: Prostate cancer was a major cause of death during the first decade after RT for patients with clinically localized but high-risk disease, and the cause of death for patients with a short PSA DT after RT was nearly always prostate cancer. These data provide evidence to propose the hypothesis that a short posttreatment PSA DT may serve as a possible surrogate for PCSD. Prospective validation is needed.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. E. Ray, K. Bae, M. H. A. Hussain, G. E. Hanks, W. U. Shipley, and H. M. Sandler Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial J Natl Cancer Inst, February 18, 2009; 101(4): 228 - 236. [Abstract] [Full Text] [PDF]

				W. D. Stein, J. Yang, S. E. Bates, and T. Fojo Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage Oncologist, October 1, 2008; 13(10): 1055 - 1062. [Abstract] [Full Text] [PDF]

				W. D. Stein, W. D. Figg, W. Dahut, A. D. Stein, M. B. Hoshen, D. Price, S. E. Bates, and T. Fojo Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data Oncologist, October 1, 2008; 13(10): 1046 - 1054. [Abstract] [Full Text] [PDF]

				S. F. Shariat, P. I. Karakiewicz, N. Suardi, and M. W. Kattan Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature Clin. Cancer Res., July 15, 2008; 14(14): 4400 - 4407. [Abstract] [Full Text] [PDF]

				M. R. Smith, J. Manola, D. S. Kaufman, W. K. Oh, G. J. Bubley, and P. W. Kantoff Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy J. Clin. Oncol., June 20, 2006; 24(18): 2723 - 2728. [Abstract] [Full Text] [PDF]

				S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy Clin. Cancer Res., December 15, 2005; 11(24): 8669 - 8673. [Abstract] [Full Text] [PDF]

				A. J. Stephenson and J. A. Eastham Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8198 - 8203. [Abstract] [Full Text] [PDF]

				C. Kadoch, A. V. D'Amico, and R. H. Matthews When Prostate Brachytherapy Fails: A Case Report and Discussion Oncologist, November 1, 2005; 10(10): 799 - 805. [Abstract] [Full Text] [PDF]

				P. Zhou, M.-H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D'Amico Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy J. Clin. Oncol., October 1, 2005; 23(28): 6992 - 6998. [Abstract] [Full Text] [PDF]

				W. K. Oh High-Risk Localized Prostate Cancer: Integrating Chemotherapy Oncologist, October 1, 2005; 10(suppl_2): 18 - 22. [Abstract] [Full Text] [PDF]

				S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey, P. C. Walsh, and A. W. Partin Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy JAMA, July 27, 2005; 294(4): 433 - 439. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, A. A. Renshaw, B. Sussman, and M.-H. Chen Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy JAMA, July 27, 2005; 294(4): 440 - 447. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]

				E. Rosenbaum, M. Zahurak, V. Sinibaldi, M. A. Carducci, R. Pili, M. Laufer, T. L. DeWeese, and M. A. Eisenberger Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial Clin. Cancer Res., June 15, 2005; 11(12): 4437 - 4443. [Abstract] [Full Text] [PDF]

				M. R. Smith, F. Kabbinavar, F. Saad, A. Hussain, M. C. Gittelman, D. L. Bilhartz, C. Wynne, R. Murray, N. R. Zinner, C. Schulman, et al. Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer J. Clin. Oncol., May 1, 2005; 23(13): 2918 - 2925. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				M. Eisenberger and A. Partin Progress toward Identifying Aggressive Prostate Cancer N. Engl. J. Med., July 8, 2004; 351(2): 180 - 181. [Full Text] [PDF]

				G. J. Kelloff, D. S. Coffey, B. A. Chabner, A. P. Dicker, K. Z. Guyton, P. D. Nisen, H. R. Soule, and A. V. D'Amico Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3927 - 3933. [Full Text] [PDF]

				A. J. Stephenson, S. F. Shariat, M. J. Zelefsky, M. W. Kattan, E. B. Butler, B. S. Teh, E. A. Klein, P. A. Kupelian, C. G. Roehrborn, D. A. Pistenmaa, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy JAMA, March 17, 2004; 291(11): 1325 - 1332. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, J. W. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M.-H. Chen Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy J Natl Cancer Inst, September 17, 2003; 95(18): 1376 - 1383. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, J. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M.-H. Chen Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era J. Clin. Oncol., June 1, 2003; 21(11): 2163 - 2172. [Abstract] [Full Text] [PDF]